$4.32
2.70% yesterday
Nasdaq, Nov 26, 10:00 pm CET
ISIN
US03589W1027
Symbol
ANNX

Annexon Inc Stock price

$4.32
+0.78 22.03% 1M
+2.21 104.74% 6M
-0.81 15.79% YTD
-0.97 18.34% 1Y
-1.44 25.00% 3Y
-20.31 82.46% 5Y
-13.44 75.68% 10Y
-13.44 75.68% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
-0.12 2.70%
ISIN
US03589W1027
Symbol
ANNX
Industry

Key metrics

Basic
Market capitalization
$625.2m
Enterprise Value
$436.5m
Net debt
positive
Cash
$188.7m
Shares outstanding
115.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.9
Financial Health
Equity Ratio
83.7%
Return on Equity
-47.2%
ROCE
-117.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-216.0m | $-224.6m
EBIT
$-218.1m | $-199.1m
Net Income
$-209.3m | $-161.1m
Free Cash Flow
$-176.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-66.9% | -47.9%
EBIT
-65.8% | -29.2%
Net Income
-77.3% | -16.6%
Free Cash Flow
-67.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.4
FCF per Share
$-1.5
Short interest
6.9%
Employees
103
Rev per Employee
$0.0
Show more

Is Annexon Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.

Annexon Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Annexon Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Annexon Inc forecast:

Buy
93%
Hold
7%

Financial data from Annexon Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 33 33
3% 3%
-
- Research and Development Expense 185 185
87% 87%
-
-216 -216
67% 67%
-
- Depreciation and Amortization 2.16 2.16
0% 0%
-
EBIT (Operating Income) EBIT -218 -218
66% 66%
-
Net Profit -209 -209
77% 77%
-

In millions USD.

Don't miss a Thing! We will send you all news about Annexon Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Annexon Inc Stock News

Positive
Seeking Alpha
7 days ago
Annexon Inc. (ANNX) is still a "Buy" in my view, driven by progress in its c1q inhibitor pipeline for rare diseases. ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA discussions. Vonaprument, targeting dry age-related macular degeneration patients with geographic atrophy, is in phase 3 testing with topline data expected in 2nd h...
Neutral
GlobeNewsWire
13 days ago
BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the closing of its previously announced underwritten public offering of 29,423,075 shares of its common stock, ...
Neutral
GlobeNewsWire
14 days ago
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 25,096,153 shares of its common stock a...
More Annexon Inc News

Company Profile

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in South San Francisco, CA.

Head office United States
CEO Douglas Love
Employees 103
Founded 2011
Website annexonbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today